Skip to main content

Table 2 Summary of published studies of CYP17 and breast cancer

From: Future possibilities in the prevention of breast cancer: Role of genetic variation in breast cancer prevention

        CYP17 (A2/A2 versus A1/A1) and breast cancer  
        All cases Advanced cases  
Ref Study design Race/ethnicity Age of patients (years) Age of control individuals (years) Cases (n) Advanced cases (n) OR 95% CI OR 95% CI HRT use considered?
[7*] Nested case-control Afro-American, Asian, Latina 63.0 ± 8.4 61.4 ± 8.3 174* 40 1.32 0.87-2.0 2.5 1.07-5.94 No
[16] Case-control White <55 45-74 835 24 1.17 0.92-1.49 0.88 0.38-2.01 No
[17] Nested case-control White 60.4 ± 11.7 60.2 ± 11.5 115 30 0.89 0.41-1.95 1.39 0.26-7.28 Yes
[18] Case-control Afro-American Not given Not given 76 21 1.40 0.44-4.38 0.6 0.1-4.0 No
   Latina    20 7 1.93 0.75-5.01 0.2 0.0-1.3  
   White    27 10 0.80 0.45-1.43 1.7 0.6-5.1  
[19*] Nested case-control White 58.3 ± 7.1   464 107 0.91 0.61-1.34 0.84 0.54-1.32 Yes
[9*] Case-control Taiwanese Not given Not given 150 Not given 1.28 0.73-2.27    Yes
[20] Case-control White 59 (27-91) 20-44 510 93§ 0.94 0.54-1.65 1.38§ 0.62-3.06 No
  1. Ages are expressed as mean ± standard error, mean (range), orrange. *Total cases, not specified by ethnicity;odds ratio (OR) reflects A1/A2 + A2/A2 combined;age not specified by case-control status;§advanced cases over age 55 years.